GSK slims portfolio with sale of rare disease gene therapy drugs

LONDON (Reuters) - GlaxoSmithKline is divesting its rare disease gene therapy drugs to Orchard Therapeutics, it said on Thursday, as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker's pharmaceuticals portfolio.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news